HRS-4642 combined with nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma: study protocol of a single-arm, prospective phase Ib/II trial

HRS-4642 combined with nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma: study protocol of a single-arm, prospective phase Ib/II trial

BackgroundPancreatic tumors are highly lethal and a leading cause of cancer mortality. While systemic chemotherapy is the mainstay for advanced disease, its efficacy remains limited. KRAS mutations occur in approximately 88% of pancreatic ductal adenocarcinoma (PDAC), of which KRAS G12D comprises up...

Full description

Saved in:
Bibliographic Details
Main Authors: Qingqing Leng, Jitao Zhou, Xin Wang, Pei Zhang, Huanji Xu, Dan Cao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Pharmacology
Subjects:
pancreatic ductal adenocarcinoma
KRAS G12D mutation
HRS-4642
nimotuzumab
combination therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1562481/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items